Literature DB >> 8180013

Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.

S M Lee1, G P Margison, N Thatcher, P J O'Connor, D P Cooper.   

Abstract

There is increasing evidence to indicate that O6-methyldeoxyguanosine (O6-MedG) formation in DNA is a critical cytotoxic event following exposure to certain anti-tumour alkylating agents and that the DNA repair protein O6-alkylguanine-DNA alkyltransferase (ATase) can confer resistance to these agents. We recently demonstrated a wide inter-individual variation in the depletion and subsequent regeneration of ATase in human peripheral blood lymphocytes following sequential DTIC (400 mg m-2) and fotemustine (100 mg m-2) treatment, with the nadir ATase activity occurring approximately 4 h after DTIC administration. We have now measured the formation and loss of O6-methyldeoxyguanosine (O6-MedG) in the DNA of peripheral leucocytes of eight patients receiving this treatment regimen. O6-MedG could be detected within 1 h and maximal levels occurred approximately 3-5 h after DTIC administration. Following the first treatment cycle, considerable inter-individual variation was observed in the peak O6-MedG levels, with values ranging from 0.71 to 14.3 mumol of O6-MedG per mol of dG (6.41 +/- 5.53, mean +/- s.d.). Inter- and intra-individual variation in the extent of O6-MedG formation was also seen in patients receiving additional treatment cycles. This may be a consequence of inter-patient differences in the capacity for metabolism of DTIC to release a methylating intermediate and could be one of the determinants of clinical response. Both the pretreatment ATase levels and the extent of ATase depletion were inversely correlated with the amount of O6-MedG formed in leucocyte DNA when expressed either as peak levels (r = -0.59 and -0.75 respectively) or as the area under the concentration-time curve (r = -0.72 and -0.73 respectively). One complete and one partial clinical response were seen, and these occurred in the two patients with the highest O6-MedG levels in the peripheral leucocyte DNA, although the true significance of this observation has yet to be established.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8180013      PMCID: PMC1968902          DOI: 10.1038/bjc.1994.165

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Studies in gastric carcinogenesis. IV. O6-methylguanine and its repair in normal and atrophic biopsy specimens of human gastric mucosa. Correlation of O6-alkylguanine-DNA alkyltransferase activities in gastric mucosa and circulating lymphocytes.

Authors:  S A Kyrtopoulos; P Ampatzi; P Davaris; N Haritopoulos; B Golematis
Journal:  Carcinogenesis       Date:  1990-03       Impact factor: 4.944

2.  Promutagenic methylation damage in bladder DNA from patients with bladder cancer associated with schistosomiasis and from normal individuals.

Authors:  A F Badawi; M H Mostafa; T Aboul-Azm; N Y Haboubi; P J O'Connor; D P Cooper
Journal:  Carcinogenesis       Date:  1992-05       Impact factor: 4.944

3.  Determination of N7-methylguanine in DNA of white blood cells from cancer patients treated with dacarbazine.

Authors:  J H van Delft; A M van den Ende; H J Keizer; J Ouwerkerk; R A Baan
Journal:  Carcinogenesis       Date:  1992-07       Impact factor: 4.944

4.  Induction and time course of DNA single-strand breaks in lymphocytes from patients treated with dacarbazine.

Authors:  S A Walles; U Ringborg
Journal:  Carcinogenesis       Date:  1991-06       Impact factor: 4.944

5.  Suppression of human DNA alkylation-repair defects by Escherichia coli DNA-repair genes.

Authors:  L Samson; B Derfler; E A Waldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

6.  Comparison of virus reactivation, DNA base damage, and cell cycle effects in autologous human melanoma cells resistant to methylating agents.

Authors:  I P Hayward; P G Parsons
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

7.  Interaction of the carcinogen 3,3-dimethyl-1-phenyltriazene with nucleic acids of various rat tissues and the effect of a protein-free diet.

Authors:  P Kleihues; G F Kolar; G P Margison
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

8.  Radioimmunoassay of O6-methyldeoxyguanosine in DNA of cells alkylated in vitro and in vivo.

Authors:  C P Wild; G Smart; R Saffhill; J M Boyle
Journal:  Carcinogenesis       Date:  1983-12       Impact factor: 4.944

9.  Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.

Authors:  S M Lee; N Thatcher; M Dougal; G P Margison
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

10.  The detection of alkylation damage in the DNA of human gastrointestinal tissues.

Authors:  C N Hall; A F Badawi; P J O'Connor; R Saffhill
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

View more
  3 in total

1.  Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity.

Authors:  A Boiardi; A Silvani; E Ciusani; A Watson; G Margison; E Berger; C Lucas; B Giroux
Journal:  J Neurooncol       Date:  2001-04       Impact factor: 4.130

2.  High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.

Authors:  Michele Guida; Antonio Cramarossa; Ettore Fistola; Mariangela Porcelli; Giuseppe Giudice; Katia Lubello; Giuseppe Colucci
Journal:  J Transl Med       Date:  2010-11-10       Impact factor: 5.531

3.  Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315.

Authors:  Ketil André Camilio; Gerd Berge; Chandra Sekhar Ravuri; Oystein Rekdal; Baldur Sveinbjørnsson
Journal:  Cancer Immunol Immunother       Date:  2014-03-28       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.